THOUSAND OAKS, Calif.,
Oct. 22, 2019 /PRNewswire/ -- Amgen
(NASDAQ: AMGN) today announced the planned retirement of
David W. Meline, who has served as
the company's executive vice president and chief financial officer
(CFO) since 2014. Meline will serve as CFO through the
end of 2019 and remain at the company into the second quarter of
2020 to help ensure a smooth transition of his responsibilities.
The company also announced that Peter H.
Griffith has joined Amgen as executive vice president,
Finance, and will be Meline's successor as CFO as of
Jan. 1, 2020.
"I am grateful to David for the many contributions he has made
to Amgen's success," said Robert A.
Bradway, chairman and chief executive officer. "David
has played an essential role in the enterprise-wide transformation
that has enabled Amgen to deliver outstanding financial performance
to our shareholders, while also investing heavily in new product
launches, research and development, and global
expansion. Additionally, under David's leadership, Amgen has
built and embedded a set of productivity capabilities throughout
our organization that position us for continued success in a highly
dynamic external environment."
Meline joined Amgen from 3M, where
he was senior vice president and CFO. Previously, Meline held
numerous senior-level roles at General Motors, including vice
president and CFO for GM North America.
"A hallmark of Amgen's nearly 40-year history has been
well-planned transitions of key leadership roles," Bradway
said. "I am delighted to welcome Peter to Amgen. His extensive
global experience and financial skills will be instrumental to our
strategy for investing in innovation to drive long-term
growth. I am pleased that David will remain with Amgen into
2020 to work with Peter and ensure a smooth transition."
Griffith joins Amgen from Sherwood Canyon Group, LLC, a private
equity and advisory firm, where he served as president. Previously,
he retired from EY (formerly Ernst & Young), a leader in
assurance, tax, transaction and advisory services, after a
distinguished career there, including almost 22 years as a
partner. Most recently, Griffith served as EY's Global Vice
Chair, Corporate Development with responsibility for driving the
firm's international growth and expanding its capabilities
worldwide. He previously served as EY's Global Managing
Partner, Finance and Corporate Development and, before that, as
Global Managing Partner, Operations and Finance during a time when
the organization grew annual revenues more than 25% to over
$27 billion. This latter role
included the Finance and Accounting, Corporate Development, Tax,
and Treasury functions. During his tenure, Griffith served on the
EY Global Executive Board, the EY Americas Executive Board, and the
Executive Board of Ernst & Young LLP. Prior to EY, he was
Managing Director and Head of Investment Banking at Wedbush
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be the world's
largest independent biotechnology company, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
CONTACT: Amgen, Thousand
Jessica Akopyan, 805-447-0974
Trish Hawkins, 805-447-5631
Arvind Sood, 805-447-1060
View original content to download